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Effects of Torcetrapid on Carotid Atherosclerosis in Familial
Hypercholesterolemia
Kastelein JJP, van Leuven SI, Burgess L, and the RADIANCE 1 Investiga-
tors. N Engl J Med 2007;356:1620-30.
Conclusion:Torcetrapid (Pfizer, New York, NY) added to atorvastatin
when compared with atorvastatin alone does not result in further reduction
of progression of atherosclerosis.
Summary: Torcetrapid is an inhibitor of cholesterol esterase transfer
protein. It can increase levels of high-density lipoprotein (HDL) cholesterol
and therefore may reduce atherosclerotic vascular disease. In this study, 850
patients with heterozygous familial hypercholesterolemia were followed up
with B-mode ultrasonography for measurement of changes in carotid
intima-media thickness. Scans were performed at baseline and at 24 months,
with interim follow-up scans at 6, 12, and 18months. Patients underwent an
atorvastatin run-in period and then were randomized to receive either
atorvastatin monotherapy or atorvastatin combined with 60 mg of Torce-
trapid for 2 years.
In the atorvastatin-only group, at 24 months, the mean ( standard
deviation) HDL cholesterol level was 52.4  13.5 mg/dL. The mean
low-density lipoprotein (LDL) cholesterol level was 143.2  42.2 mg/dL.
This was compared with 81.5  22.6 mg/dL and 115.1  48.5 mg/dL,
respectively, in the Torcetrapid-atorvastatin group. Systolic blood pressure
increased by 2.8 mm Hg in the Torcetrapid-atorvastatin group compared
with those taking atorvastatin only.
Carotid intima-media thickness was the primary measure of efficacy.
Intima-media thickness in the carotid increased 0.0053 0.0028 mm/y in
the atorvastatin-only group and increased 0.0047  0.0028 mm/y in the
Torcetrapid-atorvastatin group (P  .87). The secondary efficacy measure
was an annualized change in mean carotid intima-media thickness for the
common carotid artery. This decreased 0.0014 mm/y in the atorvastatin-
only group but increased 0.0038 mm/y in the Torcetrapid-atorvastatin
group (P  .005).
Comment: Despite a large increase in HDL cholesterol levels and a
significant decrease in LDL cholesterol levels in the Torcetrapid-atorvastatin
group, the addition of Torcetrapid to atorvastatin did not result in a
reduction of progression of atherosclerosis and, in fact, was associated with
progression of disease in the common carotid artery. This result was unex-
pected, because previous extensive epidemiologic and clinical intervention
studies had suggested significant benefit with the addition of Torcetrapid.
The authors propose that the increase in systolic blood pressure may have
had an adverse effect on carotid intima-media thickness in the atorvastatin
plus Torcetrapid group, postulating the ability of HDL to induced vasore-
laxation may have been adversely affected by Torcetrapid.
Endoluminal Therapy in Patients with Peripheral Arterial Disease:
Prospective Assessment of Quality of Life in One Hundred Ninety
Patients
Deutschmann HA, Schoellnast H, Temmel W. Am J Radiol 2007;188:
169-75.
Conclusion: Successful peripheral endovascular revascularization
(PER) results in improved quality of life for both patients with claudication
and critical limb ischemia.
Summary: The authors evaluated prospectively changes in quality of
life in 190 patients before PER and at 1, 3, 6, and 12months after treatment.
Quality of life was assessed using the Medical Outcomes Study Short
Form-36 (SF-36). The authors evaluated the effects of PER and quality of
life in both claudication and critical limb ischemia patients. The influence of
lesion location, restenosis, and additional interventions on quality of life was
also evaluated.
Data were available in 136 patients at 6 months and in 103 patients at
12 months. Patients with technically successful primary interventions, de-
fined as residual stenosis 30%, when compared with patients with techni-
cally unsuccessful interventions, defined as residual stenosis 30%, showed
significantly lower scores for bodily pain and physical functioning at 1
month, for bodily pain at 3 months, and for bodily pain and social function-
ing at 6 months. Patients with restenosis, followed by successful secondary
intervention, showed numerous differences in SF-36 scores at 1, 3, and 6
months compared with patients who underwent a primary intervention that
was initially successful. At 12 months, patients with restenosis, followed by
secondary intervention, had lower scores for vitality, mental health, and
general health perception. Patients with a significant stenosis diagnosed
during follow-up with no secondary intervention had lower scores for
physical functioning, vitality, bodily pain, and general health perception at 1
month compared with patients without stenosis. They also had lower scores
for bodily pain, general health perception at 3 months, lower scores for
physical functioning and social functioning at 6months, and lower scores for
physical function, vitality, social function, and bodily pain at 12 months.
Patients who had deterioration in their clinical symptoms had signifi-
cantly lower scores for all SF-36 domains at 1, 3, and 6 months. They also
had lower scores for all domains at 12 months, except those for role
limitations due to emotional problems and social function.
Follow-up examinations were performed to objectively assess stenosis
in 93 patients (49%) and a significant restenosis was detected in 60.2%. In 43
cases, the restenosis was at the site of intervention, and new lesions were
found in the ipsilateral leg in five cases and in the contralateral leg in eight
cases. Development of restenosis was related to lower scores at 1 month in
the domains of physical functioning, role limitations due to emotional
problems, vitality, mental health, bodily pain, and general health perception.
At 3 months, restenosis was associated with lower scores in terms of vitality,
bodily pain, and general health perception. At 6 months, lower scores were
observed in patients with restenosis for role limitations due to emotional
problems, vitality, bodily pain, and general health perception. At 12months,
restenosis was associated with lower scores for physical functioning, vitality,
mental health, social function, bodily pain, and general health perception.
Patients with claudication when compared with patients with critical
limb ischemia showed lower scores for physical functioning, role limitations
due to physical problems, role limitations due to emotional problems,
vitality, and bodily pain at baseline. At 12 months after the initial interven-
tion, no significant difference was noted in scores between claudication
patients and patients with critical limb ischemia.
Comment: This study is difficult to understand. It is certainly expected
that many of the peripheral interventions would eventually fail and that
failure of the peripheral intervention would be associated with lower SF-36
scores in many domains. It also is understandable that patients with critical
limb ischemia would have lower SF-36 scores than patients with claudica-
tion. However, it makes no sense that patients with claudication and critical
limb ischemia should have similar SF-36 scores at 12 months. It is unclear
whether patients with critical limb ischemia have substantially improved after
their intervention or that patients with claudication substantially worsened
after their intervention, or a combination of both.
Incidence of Colonic Ischemia After Repair of Ruptured Abdominal
Aortic Aneurysm with Endograft
Champagne BJ, Lee EC, Valerian B. J Am Coll Surg 2007;204:597-602.
Conclusion: There is a 23% incidence of colon ischemic after endovas-
cular repair (EVAR) of a ruptured abdominal aortic aneurysm (rAAA).
Summary: Colon ischemia after rAAA may occur in up to 42% of cases
repaired openly (J Vasc Surg 2004;39:792-796). With transmural necrosis,
mortality may be as high as 90% (Surgery 1991;109:447). When feasible,
endovascular repair of rAAAs appears to result in lower mortality. The
authors sought to determine if endovascular repair of a rAAA results in a
lower incidence of ischemic colitis than that after open repair.
The authors identified patients who underwent EVAR of a rAAA from
January 2002 to January 2006. Patients underwent flexible sigmoidoscopy
within 48 hours of repair. Patients with grades I and II colonic ischemia were
treated medically and on a selective basis with repeat colonoscopy. Patients
with grade III ischemia underwent bowel resection.
A total of 44 patients underwent EVAR for rAAA during the study
time. Operative mortality was 11%. Eighty-nine patients survived 24
hours; of these, 36 underwent sigmoidoscopy and bowel ischemia was
documented in eight (23%). Five patients had grade I or II ischemia at both
the initial and repeat endoscopy. Three patients underwent laparotomy and
bowel resection for grade III ischemia.
Comment: It is difficult to know what to make of the results of this
study. Patients treated with endografts for rAAA may be more stable than
those treated with open procedures. Because colonic ischemia has been
associated with perioperative hypotension and use of vasoactive drugs in
patients undergoing open rAAA repair, it is logical that colonic ischemia
should be lower in patients who undergo endovascular repair of a rAAA.
Nevertheless, it is nice to know the expected incidence of colonic ischemia
after EVAR for rAAA. It is also very important to realize EVAR for rAAA
does not prevent the occurrence of colonic ischemia.
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